PharBioMed's Life Sciences Consulting practice partners with BioPharma, MedTech, IVD, biotech, and digital health organizations to navigate the strategic decisions that determine portfolio value, market position, and long-term growth.
We combine deep functional expertise across the evidence lifecycle — clinical development, regulatory, Medical Affairs, commercial, market access, HEOR, and pharmacovigilance — with AI-augmented analytics from our prototype platform portfolio. The result is faster diagnostics, sharper recommendations, and consulting deliverables that are grounded in real-world data rather than slideware assertions.
Rising development costs and lengthening clinical timelines are compressing returns. Companies must make sharper portfolio choices, prioritize assets with differentiated value, and exit programs earlier when evidence does not support investment.
Payer scrutiny, outcomes-based contracts, and global pricing reform have permanently changed launch economics. Pricing strategy must be evidence-led from Phase II onward, not assembled at launch.
High-prevalence disease areas remain attractive but crowded, while precision medicine and rare disease offer niche economics. Each path requires distinct evidence, access, and commercial models — and capital allocation accordingly.
Real-world data, claims, and GenAI tooling are reshaping discovery, evidence generation, and commercialization. Companies that operationalize AI early — not just pilot it — will lead the next decade of value creation.
From the boardroom to the bench, from launch strategy to operational transformation — end-to-end advisory across the life sciences value chain.
Where to play, where to win, where to exit
Setting direction in life sciences is no longer a once-every-five-years exercise. Strategy must continually re-test itself against shifting reimbursement, competitive dynamics, and pipeline reality. We help executive teams build a clear strategic narrative, allocate capital to the highest-return assets, and create the governance to course-correct as the environment evolves.
From launch readiness to life-cycle leadership
A successful franchise is no longer about share-of-voice or a single product launch — it is about wrapping the molecule in technology, services, and evidence that together form a defensible integrated solution. Cost-conscious payers, outcomes-focused providers, and increasingly informed patients are rewarding companies that deliver demonstrable value, not just regulatory approval. We support every step from pre-launch readiness to mature-asset life-cycle defense, and from single-product strategy to multi-asset franchise leadership in a disease area.
The strategic third pillar alongside R&D and Commercial
Modern Medical Affairs is no longer a support function — it is the scientific engine that earns external trust, shapes evidence narratives, and informs commercial strategy. Our deep Medical Affairs benchhelps clients build a mature, high-impact medical organization.
Build the evidence that earns approval and reimbursement
The bar for evidence has risen: regulators want efficacy and safety, payers want value, and prescribers want differentiation. We help R&D leaders design clinical and evidence programs that satisfy all three audiences from Phase I onward.
Navigating EU MDR, FDA pathways, and digital-first business models
Medical devices, in-vitro diagnostics, and digital therapeutics operate in a regulatory and reimbursement environment fundamentally different from BioPharma. We bring purpose-built MedTech expertise from our regulatory consulting bench combined with commercial strategy depth.
Identify, evaluate, and integrate deals with confidence
Pipeline gaps cannot be filled solely through internal innovation. Whether you are searching for in-licensing opportunities, evaluating M&A targets, or considering a divestiture, we bring rigorous diligence and an independent perspective to deal decisions.
Lean operations + AI-augmented workflows = compounding advantage
Operational scale and digital maturity now separate leaders from followers. We help life sciences organizations modernize how they work — from organizational design to AI tooling — without losing the scientific rigor that defines the industry.
Mid-cap to large-cap pharma navigating launch readiness, portfolio choices, Medical Affairs scale-up, and global market access. We work across therapeutic areas including oncology, immunology, neurology, rare disease, and cardiometabolic.
Clinical-stage and pre-commercial biotechs preparing for first launch, evidence strategy, BD&L conversations, and IPO/transaction readiness. Includes platform companies, single-asset companies, and gene/cell therapy specialists.
Medical device, IVD, and combination-product manufacturers navigating EU MDR/IVDR transitions, FDA pathway selection, clinical evaluation strategy, and commercial market entry. Includes companion diagnostic developers.
Software-as-Medical-Device, digital therapeutics, AI/ML diagnostics, and platform companies bridging tech and regulated healthcare. Focus areas include reimbursement strategy, regulatory pathway, and evidence generation.
Generic and biosimilar manufacturers building differentiated positions through service wrap-arounds, geographic expansion, and complex generics strategy. Specialty pharma navigating niche commercial models.
Mid-size CROs, central labs, specialty service providers, and consulting partners seeking strategic advisory on positioning, M&A, and capability expansion in BioPharma and MedTech adjacencies.
We tailor our model to the question, not the other way around. Choose the engagement format that fits the decision you need to make.
Focused diagnostic on a single high-stakes question — opportunity sizing, vendor evaluation, capability assessment, or risk diagnostic. Ends with an executive readout and clear go/no-go recommendation.
End-to-end strategy development with full deliverables — situation analysis, options assessment, recommendation, implementation roadmap, and stakeholder communication plan. Includes executive workshops and steering committee cadence.
Dedicated consulting team embedded with your function for sustained transformation — launch readiness, Medical Affairs scale-up, post-merger integration, or AI capability build. Includes hands-on execution alongside strategy.
Fractional senior advisory model — 4 to 12 hours per month of ongoing access to a senior PharBioMed advisor. Used for strategic sounding-board, board prep, BD&L screening, and on-call expert consultation.
Our consultants have run Medical Affairs functions, processed ICSRs, drafted CSRs, built regulatory submissions, and shipped real platforms — not just written about them. Recommendations come with implementation playbooks because we have done the work.
Our 15+ prototype AI platforms shorten diagnostic cycles — RWE landscape scans, KOL identification, claims analytics, and literature synthesis that would take weeks of analyst time complete in days. You pay for senior judgment, not analyst hours.
Unlike pure strategy firms, we have an in-house CRO team across clinical data, biostatistics, pharmacovigilance, medical writing, and regulatory. Recommendations are validated against real delivery feasibility, not theory.
Top-tier strategy work without top-tier overhead. Engagements are scoped tightly, priced transparently, and delivered by senior consultants — not junior associates carrying the engagement.
We do not sell software licenses, take rebates from data vendors, or have downstream service obligations clouding our recommendations. Our advice is independent of any commercial conflict.
Domain expertise across oncology, immunology, neurology, cardiometabolic, rare disease, and infectious disease — combined with cross-functional fluency in clinical, regulatory, Medical Affairs, commercial, and HEOR.
Tell us the question you are trying to answer. We will tell you honestly whether we are the right consulting partner — and if not, we will point you to who is. No high-pressure sales, no SOW before scope is clear.